The agency said Relpax had been shown in clinical trials to provide relief for migraine headaches and all the symptoms associated with them, such as nausea and sensitivity to light and sound.
Agency president Marina Maher said Relpax will focus on women. According to the US National Headache Foundation, women are three times more likely to have migraines than men.
Maher said there was a trend for drug companies to seek more consumer expertise. ‘Part of our heritage is in beauty products,’ she said. ‘We’re good at marketing to that community. There’s no reason why pharma companies can’t do the same.’
The agency recently hired three people to focus on the healthcare arena.